Moderna shares boosted by estimate-topping financials

2 May 2024
moderna_big

Shares in US mRNA specialist Moderna (Nasdaq: MRNA) were 7% higher during Thursday morning’s trading.

The Boston-based company earlier announced its financial results for the first quarter of 2024 and its latest estimates for the year ahead.

"This is the start of a banner year for our vaccine platform"Total revenue for the quarter was $167 million, compared to $1.9 billion in the same period in 2023. The decline was primarily due to reduced sales of the company's Spikevax COVID-19 vaccine. Indeed, revenue from the shot dropped roughly 90% from the same period a year ago. Of the $167 million in Spikevax sales,  $100 million came in the USA and $67 million were elsewhere.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology